Skip to content
MARKETS / BALCAO / GTHP
BALCAO · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS · SMALL CAP

Guided Therapeutics Inc. GTHP

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$767,000
▲ 10857.1% YoY
$-3.2M
$-1.1M
Growth
USD 767,000.00
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.8 · Net income -3.2
2M-4M-8M201020122014201620182020202220242025
Compound annual growth
+289.3%
+49.7%
+33.7%
−9.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +49.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−417 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -309.3% · Net -416.7%
-10000%-20000%-30000%201020122014201620182020202220242025
ROE
FY2013 · ROE -1406.4%
-500%-1000%201020122014201620182020202220242025

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -1.1
-0.8M-1.6M201020122014201620182020202220242025

Total assetsUSD 1.3M
EquityUSD -6.0M
CashUSD 63,000.00
Current ratio0.09×

Equity funds -454% of total assets.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0··−0.0−0.0
Income tax $B0.00.00.00.00.00.00.00.00.00.0······
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0··−0.0······
EPS, diluted $−0.04−0.05−0.07−0.15−0.18−0.04−0.580.010.00−24.62−5939.38−13.02−0.16−0.08−0.14−0.12
Dividend / sh $················
Payout %················
ROE %············−1406.4−321.3−513.1−280.9
Shares out B0.090.070.050.050.010.010.000.000.000.000.000.000.000.000.000.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 3 failures · 5 divergences in 78 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 5 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 16 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente3 failures5 divergent
ActivityElectromedical & Electrotherapeutic Apparatus
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image